Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.
Neurotoxicity developed in 22 of 97 children and adolescents with malignant solid tumors treated within a phase II ifosfamide protocol. The occurrence of neurotoxicity was related to previous cumulative dosages of cisplatin. One third of the patients who had received more than 600 mg/m2 of cisplatin developed this complication. The relative risk increased 3.2-fold with previous cisplatin dosages above 301 to 600 mg/m2, and 4.1-fold with dosages of 601 to 1,340 mg/m2. The increased risk of neurotoxicity in patients who had received more than 600 mg/m2 of cisplatin may be related to either a decreased clearance of ifosfamide itself or of the drug's active metabolites.
Pratt
C B
CB
Departments of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101-0318.
Goren
M P
MP
Meyer
W H
WH
Singh
B
B
Dodge
R K
RK
D000293:Adolescent; D000328:Adult; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced*; D012306:Risk
D002945:Cisplatin; D007069:Ifosfamide